Molecular Imaging Reporter

分子影像记者

基本信息

  • 批准号:
    8195499
  • 负责人:
  • 金额:
    $ 15.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-01-01 至 2016-12-31
  • 项目状态:
    已结题

项目摘要

The Molecular Imaging Reporter Core (IVIIRC) is a central facility (See GENERAL RESOURCES AND ENVIR0NI\/1ENT). David Piwnica-Worms, PSO PI, also serves as Reporter Core Director. Julie Prior, B.S., is the Senior Core Manager. Ms. Prior is a seasoned Medical Research Lab Manager with 15 years experience in biomedical research/molecular imaging projects, and has been a part ofthe PSO ICMIC program here at Washington University since its inception. She has extensive experience with cell biology, tracer assays, biochemistry and all aspects of bioluminescence animal and cellular imaging as well as lab management. She is the primary technical investigator and directs two FTE's engaged in active experimentation, cloning of MIRC reporter genes, engineering constructs, and managing a catalog of vector systems for general use in reporting the regulation of genes of interest for scientists involved with ICMIC activities. Julie also actively participates in discovery research projects. The MIRC not only develops and generates new reporter constructs, cell lines and geneticallyengineered animals, but also provides expertise, materials and collaborative assistance for design and execution of the biological aspects of molecular imaging. The MIRC serves investigators with a wide range of resources and experience in niolecular biology, mammalian cell culture, and small animal experimentation. One of the most important service activities of this core is dissemination of our newly developed molecular imaging reagents and geneticallyencoded reporters to investigators within our institution, to other PSO program sites and to cancer biology investigators throughout the world (Figure 1). The MIRC has been and continues to be one of our most productive and comprehensive cores, impacting a broad range of programs throughout the world through our discovery research activities.
分子成像报告核心(IVIIRC)是一个中心设施(参见一般资源和

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Piwnica-Worms其他文献

David Piwnica-Worms的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Piwnica-Worms', 18)}}的其他基金

First-in-Human Imaging of Innate Immunity Activation with a Redox-Tuned PET Reporter
使用氧化还原调谐 PET 报告基因首次对人体进行先天免疫激活成像
  • 批准号:
    10577531
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
Molecular Imaging Core
分子成像核心
  • 批准号:
    10517142
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Molecular Imaging Core
分子成像核心
  • 批准号:
    10707122
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8658378
  • 财政年份:
    2014
  • 资助金额:
    $ 15.75万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8195493
  • 财政年份:
    2012
  • 资助金额:
    $ 15.75万
  • 项目类别:
Molecular Imaging High Throughtput Screening
分子成像高通量筛选
  • 批准号:
    8195501
  • 财政年份:
    2012
  • 资助金额:
    $ 15.75万
  • 项目类别:
Imaging and Characterizating Stress responses in vivo with p21 Reporter Mice
使用 p21 报告小鼠对体内应激反应进行成像和表征
  • 批准号:
    8195496
  • 财政年份:
    2012
  • 资助金额:
    $ 15.75万
  • 项目类别:
PET Imaging of GVHD and GVL after treatment with Azacitidine
阿扎胞苷治疗后 GVHD 和 GVL 的 PET 成像
  • 批准号:
    8195498
  • 财政年份:
    2012
  • 资助金额:
    $ 15.75万
  • 项目类别:
Core A: Molecular Imaging Reporter Core (MIRC)
核心 A:分子成像报告核心 (MIRC)
  • 批准号:
    7287034
  • 财政年份:
    2007
  • 资助金额:
    $ 15.75万
  • 项目类别:
Administration
行政
  • 批准号:
    7287029
  • 财政年份:
    2007
  • 资助金额:
    $ 15.75万
  • 项目类别:

相似海外基金

Mechanisms underlying caloric restriction-mediated resolution of atherosclerosis
热量限制介导的动脉粥样硬化解决机制
  • 批准号:
    10852754
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
Effects of early vs. late time restricted eating vs. daily caloric restriction on weight loss and metabolic outcomes in adults with obesity
早期与晚期限制饮食与每日热量限制对肥胖成人体重减轻和代谢结果的影响
  • 批准号:
    10585523
  • 财政年份:
    2023
  • 资助金额:
    $ 15.75万
  • 项目类别:
Novel Strategy to Quantitate Delayed Aging by Caloric Restriction
通过热量限制来量化延迟衰老的新策略
  • 批准号:
    10594352
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Caloric restriction-driven immunometabolic checkpoints of inflammation
热量限制驱动的炎症免疫代谢检查点
  • 批准号:
    10457565
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Caloric restriction-driven immunometabolic checkpoints of inflammation
热量限制驱动的炎症免疫代谢检查点
  • 批准号:
    10656332
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Molecular Networks in Aging and Caloric Restriction in Rhesus Monkeys
恒河猴衰老和热量限制的分子网络
  • 批准号:
    10579229
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Novel Strategy to Quantitate Delayed Aging by Caloric Restriction
通过热量限制来量化延迟衰老的新策略
  • 批准号:
    10355362
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Mechanisms underlying caloric restriction-mediated resolution of atherosclerosis
热量限制介导的动脉粥样硬化解决机制
  • 批准号:
    10677793
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Mechanisms underlying caloric restriction-mediated resolution of atherosclerosis
热量限制介导的动脉粥样硬化解决机制
  • 批准号:
    10656977
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
Time Restricted Eating As a Viable Alternative to Caloric Restriction for Treating Hyperglycemia in a Population with Type 2 (T2DM) diabetes
时间限制饮食作为热量限制的可行替代方案治疗 2 型 (T2DM) 糖尿病患者的高血糖症
  • 批准号:
    10439148
  • 财政年份:
    2022
  • 资助金额:
    $ 15.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了